Limba
|
Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAbconjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and circulation.
Price | 16.249,00 RON (preturile sunt fara TVA) |
---|---|
Description |
Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAbconjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and circulation. |